Huntington's Disease

Neurology
7
Pipeline Programs
8
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
2 programs
1
1
RO7234292Phase 22 trials
No Study Drug was Administered in this StudyPhase 11 trial
Active Trials
NCT03664804Completed95Est. May 2022
NCT03842969Completed236Est. Mar 2022
NCT03342053Completed46Est. Oct 2019
Ipsen
IpsenChina - Tianjin
1 program
1
BN82451BPhase 21 trial
Active Trials
NCT02231580Terminated17Est. Mar 2016
Teva
TevaIsrael - Petach Tikva
1 program
1
LaquinimodPhase 21 trial
Active Trials
NCT02215616Completed352Est. Jun 2018
Vaccinex
VaccinexROCHESTER, NY
1 program
1
VX15/2503Phase 21 trial
Active Trials
NCT02481674CompletedEst. Aug 2020
Ionis Pharmaceuticals
1 program
1
ISIS 443139 10 mgPhase 1/21 trial
Active Trials
NCT02519036Completed46Est. Nov 2017
Alnylam Pharmaceuticals
1 program
1
ALN-HTT02Phase 11 trial
Active Trials
NCT06585449Recruiting66Est. Jul 2028
QT
Q TherapeuticsUT - Salt Lake City
1 program
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's DiseaseN/A1 trial
Active Trials
NCT00670709CompletedEst. Feb 2008
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
FuRST 2.0N/A1 trial
Active Trials
NCT02881931CompletedEst. Jul 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
RocheRO7234292
RocheRO7234292
VaccinexVX15/2503
TevaLaquinimod
IpsenBN82451B
Ionis PharmaceuticalsISIS 443139 10 mg
Alnylam PharmaceuticalsALN-HTT02
RocheNo Study Drug was Administered in this Study
T-TherapeuticsFuRST 2.0
Q TherapeuticsExamination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Clinical Trials (10)

Total enrollment: 858 patients across 10 trials

NCT03842969RocheRO7234292

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

Start: Apr 2019Est. completion: Mar 2022236 patients
Phase 3Completed
NCT03342053RocheRO7234292

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Start: Jan 2018Est. completion: Oct 201946 patients
Phase 2Completed
NCT02481674VaccinexVX15/2503

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

Start: Jul 2015Est. completion: Aug 2020
Phase 2Completed
NCT02215616TevaLaquinimod

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

Start: Oct 2014Est. completion: Jun 2018352 patients
Phase 2Completed
NCT02231580IpsenBN82451B

Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients

Start: Sep 2014Est. completion: Mar 201617 patients
Phase 2Terminated
NCT02519036Ionis PharmaceuticalsISIS 443139 10 mg

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Start: Aug 2015Est. completion: Nov 201746 patients
Phase 1/2Completed
NCT06585449Alnylam PharmaceuticalsALN-HTT02

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Start: Oct 2024Est. completion: Jul 202866 patients
Phase 1Recruiting
NCT03664804RocheNo Study Drug was Administered in this Study

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

Start: Dec 2018Est. completion: May 202295 patients
Phase 1Completed
NCT02881931T-TherapeuticsFuRST 2.0

FuRST 2.0 Cognitive Pre-Testing

Start: Feb 2017Est. completion: Jul 2017
N/ACompleted
NCT00670709Q TherapeuticsExamination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Start: Sep 2006Est. completion: Feb 2008
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 858 patients
8 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)